Rohit Kumar, MD
Hematology & Oncology · Louisville, KYNPI 1154737724
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Pfizer at 27.1% of the total. 2025 is the largest year on record at $13,987, 2.6 times the $5,419 reported in 2019. Among hematology & oncology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 600 payments — averaging $51.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8K
- EMD Serono, Inc.$3K
- AstraZeneca$2K
- Springworks Therapeutics, Inc.$2K
- Amgen$2K
- Deciphera Pharmaceuticals Inc.$1K
- plus $11K from 48 others
Across 37 payments — averaging $42,935 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- Pfizer$147K
- Eli Lilly$40K
- Amgen$37K
- Janssen Research & Development, LLC$32K
What the payments were for
- Consulting fees$7,57325%
- Speaking & faculty fees$7,66025%
- Grants$5012%
- Food & beverage$14,33046%
- Education$8353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,898 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 59 | $1,457,004 |
| XtandiEnzalutamide | 96 | $1,385,982 |
| Abiraterone Acetate | 180 | $544,198 |
| LenvimaLenvatinib Mesylate | 19 | $469,620 |
| NubeqaDarolutamide | 35 | $463,569 |
| OrgovyxRelugolix | 36 | $95,883 |
| Everolimus | 16 | $78,948 |
| OxycontinOxycodone Hcl | 12 | $13,826 |
| EliquisApixaban | 17 | $11,984 |
| Oxycodone Hcl | 114 | $2,065 |
| Ondansetron Hcl | 22 | $1,225 |
| Prochlorperazine Maleate | 38 | $1,028 |
| Dexamethasone | 50 | $777 |
| Prednisone | 155 | $673 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $122 | $1,457,00459 claims |
| Astellas Pharma US IncXtandi | $489 | $1,385,98296 claims |
| Eisai Inc.Lenvima | $887 | $469,62019 claims |
| BayerNubeqa | $452 | $463,56935 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $182 | $95,88336 claims |
| PfizerEliquis | $8,360 | $11,98417 claims |
| Lilly USA, LLCOlanzapine | $370 | $22211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Vikas SinghLouisville$28K
- Adam LyeLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.